About EQAPOL

The External Quality Assurance Program Oversight Laboratory (EQAPOL) is a National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID)-Division of AIDS (DAIDS) funded resource located at Duke Human Vaccine Institute's (DHVI) Immunology and Virology Quality Assessment Center (IVQAC); to support the development, implementation and oversight of external quality assurance programs that monitor laboratories involved in HIV/AIDS research and vaccine trials around the world.

The EQAPOL Program consists of the following components:

  • Maintain a Peripheral Blood Mononuclear Cell (PBMC) Cell Bank and Reagent Repository
  • An Enzyme-linked Immunosorbent Spot (ELISpot) Assay External Quality Assurance (EQA) Program
  • An EQA Program for Flow Cytometry-based Assays
  • Establish and Characterize Unique Clade-Specific HIV Virus Panels
  • A Luminex EQA Program
  • Validate an A3R5 Neutralization Assay and administer an EQA Program
  • A Limiting Antigen (LAg) Avidity Incidence Assay EQA Program
  • Create a Central Web Database for the Above Activities
RTP campus imagery

Duke Human Vaccine Institute Wins Contract to Produce Pan-Coronavirus Vaccine

The Duke Human Vaccine Institute has received a federal contract to manufacture a pan-coronavirus vaccine candidate that can be tested in a phase 1 clinical trial.
 
Awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), the base period of the contract provides $11.2 million to support the program; additional provisions in the contract could increase the total funding up to $21.5 million if all option periods are exercised.

Scientist in lab

DHVI Immunology Quality Assessment (IQA) Program Receives Additional 7 year contract, Totaling 28 Consecutive Years for IQA

The Duke Human Vaccine Institute (DHVI) received a $16,218,499 (includes the base period and all options), seven-year (if all term options are exercised) contract to implement the Immunology Quality Assessment (IQA) Program from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to provide a resource to evaluate and enhance the ability of U.S. and non-U.S. laboratories to participate in NIAID-funded and collaborative clinical studies.